Mefloquine

Mefloquine Hydrochloride, the active ingredient in Mefloquine, is a quinoline antimalarial presented as an oral dosage form for oral use. It is employed for the prevention of malaria and for the treatment of acute, uncomplicated malaria caused by chloroquine‑resistant Plasmodium falciparum in adults and children.

GNH USA supplies Mefloquine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality manufacturing, regulatory compliance and reliable global logistics, and supporting patient care across malaria‑endemic regions through consistent supply chains.

Mefloquine is used in the antimalarial therapeutic class to prevent and treat infections caused by Plasmodium species. - Malaria prophylaxis: prevents infection in individuals traveling to or residing in areas with chloroquine‑resistant malaria. - Chemoprophylaxis for malaria in endemic regions: provides ongoing protection during prolonged exposure. - Acute uncomplicated malaria (chloroquine‑resistant Plasmodium falciparum): treats infection, leading to parasite clearance and symptom resolution.

Mefloquine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: transient light‑headedness. - Headache: occasional throbbing pain. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Psychiatric reactions: anxiety, depression, or psychosis. - Seizures: rare convulsive episodes. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Cardiac arrhythmias: QT interval prolongation leading to irregular heartbeat.

Before prescribing mefloquine, clinicians should consider several safety factors. - Assess contraindications: avoid in patients with known hypersensitivity to quinoline antimalarials. - Review psychiatric history: use cautiously in individuals with prior mood disorders. - Evaluate cardiac risk: monitor QT interval in patients with cardiac disease or on other QT‑prolonging drugs. - Consider hepatic function: adjust use in patients with severe liver impairment. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Mefloquine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Antiepileptic drugs (e.g., carbamazepine, phenytoin): may reduce mefloquine efficacy. - QT‑prolonging agents (e.g., quinidine, haloperidol): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may raise plasma concentrations. - CYP3A4 inducers (e.g., rifampicin, phenobarbital): may lower plasma concentrations. - Antacids: can affect gastrointestinal absorption of mefloquine.